Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis.
about
Studies of Immune Responses in Candida vaginitisEmerging drugs and vaccines for candidemiaThe protein kinase Tor1 regulates adhesin gene expression in Candida albicansActive and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infectionActive and passive immunization with rHyr1p-N protects mice against hematogenously disseminated candidiasisNDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults.Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherenceAls3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells.Gene overexpression/suppression analysis of candidate virulence factors of Candida albicans.Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice.FaaPred: a SVM-based prediction method for fungal adhesins and adhesin-like proteins.Candida infections of the genitourinary tract.The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice.Oral-resident natural Th17 cells and γδ T cells control opportunistic Candida albicans infections.Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus.Fungal vaccines and immunotherapeutics.Prospects for development of a vaccine to prevent and control vaginal candidiasis.Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection.Exploiting fungal cell wall components in vaccinesVaccines for invasive fungal infectionsNovel strategies to fight Candida species infection.IL-17 signaling in host defense against Candida albicans.Anticandidal immunity and vaginitis: novel opportunities for immune intervention.Vaccines in the treatment of invasive candidiasis.Adaptive immune responses to Candida albicans infection.New approaches in the development of a vaccine for mucosal candidiasis: progress and challengesRecent progress in vaccines against fungal diseasesAdvances in combating fungal diseases: vaccines on the thresholdConsiderable differences in vaccine immunogenicities and efficacies related to the diluent used for aluminum hydroxide adjuvant.Proteomic Analysis of Pathogenic Fungi Reveals Highly Expressed Conserved Cell Wall Proteins.Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes.The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus.Mouse model of oropharyngeal candidiasis.Discovering the secrets of the Candida albicans agglutinin-like sequence (ALS) gene family--a sticky pursuitInvestigation of the function of Candida albicans Als3 by heterologous expression in Candida glabrataInnate immune cell response upon Candida albicans infectionImmune defence mechanisms and immunoenhancement strategies in oropharyngeal candidiasis.Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunityNDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.Molecular and cellular mechanisms that lead to Candida biofilm formation.
P2860
Q26782272-8DBF7A51-0ED7-419D-B209-DDF2A760F7A6Q26828993-1B2BEC1B-B3F4-4509-AC39-7D9C09AF0DEBQ28474672-D3390128-447D-4895-8A1C-9BBB78B0D159Q28478751-4730C653-EA0B-456F-8BEE-6892D029DC92Q28744094-87F339B2-7770-4BED-A2AB-E7BD997FDE9EQ30528889-94C0D697-55DD-4CAF-B06F-90767D4F8067Q30862390-A55AB861-11BC-49C3-9DCD-27E7090600D5Q33274746-3EBEEDC6-8319-4545-8FEE-E85A188F11B9Q33313469-9953184C-9E90-43EF-B179-83B2382AB2BAQ33521257-86B65DDF-C1CC-423B-B3D5-A78D4302334EQ33543109-E54E2807-7030-406B-A6EE-ED5D59976192Q33825621-6A4B1B06-F952-4211-9ADE-F410593C8D1AQ33882951-0446549E-4FA2-4618-ACFE-CDD9E5B2AEC3Q34230506-992EAB01-F05F-47E5-8D93-04FB38200ADAQ34250054-EC2D7F9A-FC16-4BEF-B60E-248588F44C69Q34400249-27FD8660-9A88-4E38-81BD-0A8CBD842DA7Q34707478-5B7EC101-99BA-47ED-B0C2-5EB7AD57DBCFQ34792962-E231A735-E235-4177-BE81-82079C21D609Q35085200-43AE93AB-43DE-4D88-8B0C-2F9382804DF7Q35161720-EEDA2586-6B07-4626-A359-40E8FACE594BQ35406737-C245115B-F009-4D74-BC5E-96338CD55CF4Q35671394-AD43C917-A634-40E6-9672-19ACECCEF369Q36097307-9C128428-39FB-4D2F-A9DD-7D7F48951765Q36147010-D98DB24A-7749-43FE-BFC3-D54437CE2078Q36147114-EDBAC1E1-ED79-4211-9109-7299F2C66D14Q36158337-DB4EEC00-5810-46DE-B653-2A81A8347EB2Q36179629-2998A78E-BA24-45AC-BF5E-6ED825E441B7Q36406460-0C420FC2-E2DB-408B-8DD3-E5D410318545Q36497665-5ACFBF5D-D1F5-4764-BA08-8AFCC8EC74F0Q36562397-82CCDB63-58B7-4752-9B85-59AD9C063C1AQ36569183-DCC15233-29B2-456F-B2F1-3846D83283ECQ36898452-CD578FCD-63F6-467F-B414-F4BE70E460F6Q36900988-6A08A78B-561D-406F-B4F6-4554F472EF91Q36939626-A4704915-8DB8-4B73-A3C5-FA31BC39D1C2Q36970753-30D67777-6A19-4ACB-9072-C8EE7EC20383Q37262877-EF480075-221A-46A5-BB79-20332919322BQ37267375-91D199BD-BB91-4FBA-AC6A-24CB5437D94FQ37280340-DABAF3A1-AE75-4F87-BEBF-E9BD797341D7Q37399422-3FA9EEB1-82D1-47FE-ACAE-7C4995226D60Q37412802-BD685150-76D9-407B-8D60-6F55DF9BC58D
P2860
Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Efficacy of the anti-Candida r ...... nated and mucosal candidiasis.
@en
Efficacy of the anti-Candida r ...... nated and mucosal candidiasis.
@nl
type
label
Efficacy of the anti-Candida r ...... nated and mucosal candidiasis.
@en
Efficacy of the anti-Candida r ...... nated and mucosal candidiasis.
@nl
prefLabel
Efficacy of the anti-Candida r ...... nated and mucosal candidiasis.
@en
Efficacy of the anti-Candida r ...... nated and mucosal candidiasis.
@nl
P2093
P356
P1476
Efficacy of the anti-Candida r ...... nated and mucosal candidiasis.
@en
P2093
Ashraf S Ibrahim
Brad J Spellberg
Carter Myers
John E Edwards
Michael R Yeaman
Quynh T Phan
Scott G Filler
Valentina Avanesian
P304
P356
10.1086/504691
P407
P577
2006-06-06T00:00:00Z